Abstract: Formulation of vaccine antigens, containing as main components: a—) one or several DNA expressing one or several proteins in the immunized individuals and b—) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens. These formulations can be applied in the pharmaceutical industry for preventive and-or therapeutic use in human.
Type:
Grant
Filed:
April 27, 2009
Date of Patent:
April 8, 2014
Assignee:
Centro de Ingenieria Genetica y Biotecnologia
Inventors:
Santiago Duenas Carrera, Juan Morales Grillo, Liz Alvarez-Lajonchere Ponce de Leon, Alexis Musacchio Lasa, Rolando Pajon Feyt, Ariel Vina Rodriguez, Julio C. Alvarez Obregon, Nelson Acosta Rivero, Gillian Martinez Donato
Abstract: The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides immunogenic nanoemulsion compositions and methods of administering the same (e.g., via a heterologous prime/boost protocol (e.g., utilizing the same nanoemulsion in each the prime and boost administrations)) to induce immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
Type:
Application
Filed:
September 30, 2013
Publication date:
April 3, 2014
Applicants:
NANOBIO CORPORATION, THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventors:
James R. Baker, JR., Douglas Smith, Ali I. Fattom, Jakub Simon
Abstract: A transgenic soybean plant harboring an exogenous nucleic acid molecule encoding porcine reproductive and respiratory syndrome virus ORF7 immunogen and methods for using the same to induce an antibody response and prevent a porcine reproductive and respiratory syndrome virus infection are provided.
Type:
Application
Filed:
October 2, 2013
Publication date:
April 3, 2014
Applicant:
The Board of Trustees of the University of Illinois
Abstract: The disclosure provides plant vaccine compositions and methods for inducing immunity to Beet Curly Top Virus (BCTV) and related curtoviruses in a susceptible plant.
Type:
Application
Filed:
September 26, 2013
Publication date:
April 3, 2014
Inventors:
William M. Wintermantel, Laura L. Hladky
Abstract: A surface expression vector for preparing HPV immunogenic compositions, in which the surface expression vector contains a gene encoding a repE mutant protein having an amino acid sequence of SEQ ID NO: 1, a promoter, a poly-gamma-glutamate synthetase complex gene, and a gene which is linked with the poly-gamma-glutamate synthetase complex gene and encodes a tumor induction-associated antigen protein of human papillomavirus. An expression vector constitutively expressing a high level of the human papillomavirus (HPV) antigen protein is provided. Also, a recombinant lactic acid bacteria, transformed with the expression vector and expressing the HPV antigen protein on the surface thereof, and a composition comprising the recombinant lactic acid bacteria are provided. The recombinant lactic acid bacteria and the composition are very effective as a immunogenic composition for the treatment of cervical cancer, because they can be applied orally or directly to the vagina.
Type:
Grant
Filed:
January 8, 2010
Date of Patent:
April 1, 2014
Assignees:
Bioleaders Corporation, Kookmin University Industry-Academy Cooperation Foundation
Inventors:
Moon-Hee Sung, Haryoung Poo, Il Han Lee
Abstract: There is provided a T cell-based universal influenza vaccine including internal genes capable of preparing against infection by broad hetero-subtypic influenza viruses, and thereby preparing for unpredictable epidemic influenza. The present invention selected internal genes of the consensus sequence obtained from bird, pig, and human influenza isolates in order to develop the T cell-based universal flu vaccine. The T cell-based universal flu vaccine according to the present invention is characterized by including at least one CTL epitope, by containing a plurality of internal genes and using the entire sequence of the internal gene itself. The T cell-based universal flu vaccine can achieve broad defense in infection with hetero-subtypic influenza viruses.
Type:
Grant
Filed:
November 1, 2012
Date of Patent:
April 1, 2014
Assignee:
Mogam Biotechnology Research Institute
Inventors:
Jin-Won Youn, Ji-Sun Kwon, Jung-Soon Yoon, Yeon-Jung Kim
Abstract: Pharmaceutical or veterinary compositions, vaccine systems, methods, and kits for treating or protecting a subject from a condition using peptide-based adjuvants are provided. The peptide adjuvants comprise a peptide having a hydrophobic region, a turning region, and a hydrophilic region. The turning region comprises amino acid residues GSII (SEQ ID NO: 10). The peptide adjuvants can be used to immunopotentiate active agents by improving the immune response to the active agent.
Type:
Application
Filed:
May 25, 2012
Publication date:
March 27, 2014
Applicant:
KANSAS STATE UNIVERSITY RESEARCH FOUNDATION
Abstract: The invention relates to a method for producing a modified viral strain of a virus which is a member of the Reoviridae family and, in particular, relates to vaccinal viral strains of the Orbivirus genus.
Type:
Grant
Filed:
November 26, 2008
Date of Patent:
March 18, 2014
Assignee:
London School of Hygiene & Tropical Medicine
Abstract: The present invention provides recombinant replication-defective adenoviral vectors derived from chimpanzee adenoviruses and methods for generating recombinant adenoviruses in human E1-expressing cell lines. The invention also provides compositions and methods suitable for use for the delivery and expression of transgenes encoding immunogens against which a boosted immune response is desired. The invention further provides methods of generating clinical grade vector stocks suitable for use in humans. In a particular embodiment the invention contemplates the use of vectors comprising transgenes which encode tumor associated antigens in vaccines and pharmaceutical compositions for the prevention and treatment of cancer.
Type:
Grant
Filed:
June 21, 2012
Date of Patent:
March 18, 2014
Assignee:
MSD Italia SRL
Inventors:
Stefano Colloca, Alfredo Nicosia, Agostino Cirillo, Bruno Bruni Ercole, Annalisa Meola, Paolo Palazzolo
Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.
Type:
Application
Filed:
November 9, 2011
Publication date:
March 13, 2014
Applicant:
ZOETIS LLC
Inventors:
Jay Gregory Calvert, David Ewell Slade, Siao-Kun W. Welch
Abstract: The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.
Type:
Application
Filed:
November 8, 2013
Publication date:
March 6, 2014
Applicant:
Eisai R&D Management Co., Ltd.
Inventors:
Daniel P. Rossignol, Sally T. Ishizaka, Lynn D. Hawkins, Scott Fields
Abstract: The present inventors developed hepatitis C virus 2b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 2b reference strain J8. Sequence analysis of recovered 2b/2a recombinants from 2 transfection experiments revealed that 2b/2a was genetically stable. Conclusion: The developed 2b/2a viruses provide a robust in vitro tool for research in HCV genotype 2b, including vaccine studies and functional analysis.
Type:
Grant
Filed:
July 24, 2009
Date of Patent:
March 4, 2014
Assignee:
Hvidovre Hospital
Inventors:
Judith M. Gottwein, Maria Lisa Knudsen, Troels Kasper Høyer Scheel, Jens Bukh
Abstract: We provide new methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human DCs and the use thereof in cancer vaccination. The method includes the introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L, and CD70 or constitutively active TLR4 (caTLR4).
Type:
Application
Filed:
August 23, 2013
Publication date:
February 27, 2014
Applicant:
VRIJE UNIVERSITEIT BRUSSEL
Inventors:
Kris Maria Magdalena Thielemans, Aude Bonehill
Abstract: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.
Type:
Application
Filed:
August 29, 2013
Publication date:
February 27, 2014
Inventors:
Paul Joseph Dominowski, Ramasamy Mannar Mannan, Richard Lee Krebs, James Richard Thompson, Tedd Alan Childers, Mary Kathryn Olsen, Robert John Yancey, JR., Risini Dhammika Weeratna, Shucheng Zhang, Cedo Martin Bagi
Abstract: The present invention discloses liquid stable vaccines that comprise a live attenuated virus, 10-30% sugar additive, and an amino acid. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
Abstract: Minimally invasive delivery with intercellular and/or intracellular localization of nano- and micro-particle solar cells within and among excitable biological cells to controllably regulate membrane polarization and enhance function of such cells. The cells include retinal and other excitable cells.
Abstract: The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.
Type:
Application
Filed:
July 22, 2013
Publication date:
February 27, 2014
Inventors:
Wolfgang Renner, Martin F. Bachmann, Indulis Cielens, Conrad Johannes Coester, Klaus Dietmeier, Sebastian Fuchs, Vania Manolova, Patrik Maurer, Paul Pumpens, Regina Renhofa, Alain Tissot, Yu Zou
Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.
Type:
Application
Filed:
October 23, 2013
Publication date:
February 20, 2014
Applicant:
UNIVERSITAT ZURICH
Inventors:
Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
Abstract: The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population.
Type:
Grant
Filed:
October 2, 2008
Date of Patent:
February 18, 2014
Assignee:
The Board of Trustees of the University of Arkansas
Abstract: The present invention provides antisense antiviral compounds, compositions, and methods of their use and production, mainly for inhibiting the replication of viruses of the Filoviridae family, including Ebola and Marburg viruses. The compounds, compositions, and methods also relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds include phosphorodiamidate morpholino oligonucleotides (PMOplus) having a nuclease resistant backbone, about 15-40 nucleotide bases, at least two but typically no more than half piperazine-containing intersubunit linkages, and a targeting sequence that is targeted against the AUG start site region of Ebola virus VP35, Ebola virus VP24, Marburg virus VP24, or Marburg virus NP, including combinations and mixtures thereof.
Abstract: Immunogenic compositions and broad-spectrum vaccines containing newly identified isolates of canine distemper virus (CDV) collected from a geographic area are provided. The newly identified isolates exhibit attributes of both European wildlife lineage CDV and one or both of Arctic and American-2 lineage CDV. Therefore, the vaccines are broadly protective against infection with European wildlife lineage CDV and either Arctic lineage CDV or American-2 lineage CDV, or both Arctic and American-2 lineage CDV.
Type:
Grant
Filed:
January 29, 2010
Date of Patent:
February 11, 2014
Assignee:
The Board of Regents for Oklahoma State University
Abstract: The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-receptor (FXR) antagonist. The invention also relates to an adjuvant for variety of antigens. The adjuvant improves antibody production specific to incorporated antigen. The adjuvant also induces cell mediated immune response.
Abstract: The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia.
Abstract: This invention relates to compositions for delivering one or more active ingredients, and more particularly to compositions, e.g. beads, comprising a matrix material which matrix material comprises a microorganism. In particular, the invention relates to compositions comprising a microorganism selected from live, killed, attenuated and inactivated microorganisms. The matrix material may also comprise a surfactant and may further comprise an adjuvant. The invention further relates to the manufacture and use of such compositions, and to other subject matter.
Type:
Application
Filed:
July 5, 2013
Publication date:
January 16, 2014
Applicant:
Sigmoid Pharma Limited
Inventors:
Ivan Coulter, Bernard Francis McDonald, Vincenzo Aversa, Mónica Rosa
Abstract: Provided are recombinant adenovirus vectors (serotype 26 and serotype 35) encoding filovirus antigens. The adenovirus vectors can be used to induce protective immune responses against filovirus infection.
Type:
Application
Filed:
December 14, 2011
Publication date:
January 16, 2014
Inventors:
Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Maria Grazia Pau, Jaap Goudsmit
Abstract: A method for inducing mucosal immune responses in a subject in need thereof to an antigen includes administering to the subject a vaccine composition including the antigen and a Dioscorea polysaccharides as an adjuvant. Because of the immuomodulatory effect of the Dioscorea polysaccharides, the vaccine composition is further capable of breaking immunological tolerance in the subject.
Abstract: We have developed DNA and viral vectors that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can encode a variety of antigens, which may be obtained from one clade or from two or more different clades, and the antigens selected and/or the manner in which the vectors are formulated (e.g., mixed) can be manipulated to generate a protective immune response against a variety of clades (e.g., the clades to which a patient is most likely to be exposed; with the proportions of the components of the vaccine tailored to the extent of the patient's risk to a particular clade or clades).
Type:
Grant
Filed:
January 3, 2003
Date of Patent:
January 7, 2014
Assignee:
Emory University
Inventors:
Harriet L. Robinson, James Smith, Jian Hua
Abstract: The present invention relates to methods and applications of using Drosophila cells to produce virus-like particles. Virus-like particles of enveloped viruses produced by the methods of the present invention have proteins correctly expressed, cleaved, and assembled. Ultimately, virus-like particles having good immunogenicity are obtained. The present invention also provides recombinant cells expressing virus-like particles and compositions containing virus-like particles.
Type:
Application
Filed:
March 19, 2012
Publication date:
January 2, 2014
Applicant:
INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES
Inventors:
Paul Zhou, Yufeng Song, Fan Zhou, Lifei Yang, Cheguo Cai, Heng Ding
Abstract: Disclosed herein are methods and compositions for treating or preventing Porcine reproductive and respiratory syndrome (PRRS) infection in a subject.
Abstract: The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.
Abstract: Methods of purifying virus-like particles (VLPs) that are substantially free of process contaminants and infectious agents. The methods incorporate, for example, low-pH treatment during harvest and/or inactivation by a solvent and/or detergent during VLP capture.
Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A beta-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.
Type:
Grant
Filed:
May 13, 2013
Date of Patent:
December 31, 2013
Assignee:
Novartis AG
Inventors:
Ana Graf, Matthias Staufenbiel, Thomas Blaettler, Paolo Paganetti
Abstract: The present invention relates to a method for augmenting the immunogenicity of an antigen in a mammal, comprising immunizing the mammal with a composition comprising the antigen, and an adjuvant in an amount of effective to augment the immunogenicity of said antigen, wherein the adjuvant comprises a Ling-Zhi-8 (LZ-8) protein.
Abstract: The present invention provides a new means of restoring the immune system in aging and immunocompromised individuals using an antioxidant nutraceutical. The nutraceutical stimulates the aging immune system through the Nrf2 master gene regulatory pathway. The invention is based in part on the discovery that the Nrf2 has antioxidant and immune restorative activity. The nutraceutical improves function of both the innate and adaptive immune systems.
Abstract: The invention involves inactivation of viral populations by treating the viral populations with a compound to crosslink proteins in the viral membrane, UV irradiation and further inactivation of the viruses using detergent(s). According to the invention, this method preserves the native structure of viral epitopes so that the inactivated viral preparations can be used in immunological compositions that will inhibit and/or prevent viral infection when administered to an animal.
Type:
Grant
Filed:
July 30, 2010
Date of Patent:
December 24, 2013
Assignee:
The United States of America, as Represented by the Secretary, Department of Health and Human Services
Inventors:
Yossef Raviv, Julie M. Belanger, Mathias Viard, Robert Blumenthal, Julian W. Bess, Jr.
Abstract: The present invention relates to a replication deficient recombinant virus encoding at least one antigen and/or antigenic epitope, wherein expression of said antigen and/or antigenic epitope is regulated by a transcriptional control element comprising at least two elements driving early expression of said antigen and/or antigenic epitope and the use of said replication deficient recombinant virus as medicament or vaccine.
Type:
Grant
Filed:
August 30, 2011
Date of Patent:
December 24, 2013
Assignee:
Bavarian Nordic A/S
Inventors:
Jürgen Hausmann, Karen Baur, Kay Brinkmann
Abstract: The invention relates to a replication-deficient adenoviral vector comprising two or more nucleic acid sequences encoding Dengue virus antigens and a chimeric hexon protein. The chimeric hexon protein comprises a first portion and a second portion. The first portion comprises at least 10 contiguous amino acid residues from a first adenovirus serotype (e.g., serotype 5 adenovirus hexon protein), optionally with one amino acid substitution. The second portion comprises (a) at least one hypervariable region (HVR) of a hexon protein of an adenovirus of a second adenovirus serotype, or (b) at least one synthetic hypervariable region (HVR) that is not present in the hexon protein of the wild-type adenovirus of the first adenovirus serotype.
Type:
Application
Filed:
December 20, 2011
Publication date:
December 19, 2013
Applicant:
GENVEC, INC.
Inventors:
Joseph T. Bruder, Duncan McVey, Douglas E. Brough
Abstract: The present invention relates to the use of interferon in the in vitro cultivation of animal circular ssDNA virus such as Porcine Circovirus 2 or human TT virus in an animal cell line. Increased titres of animal circular ssDNA virus are obtained by addition of interferons or agents which ensure the production of endogenous interferons by said cell line and/or by the reduction of endosomal-lysosomal system acidification.
Type:
Application
Filed:
December 24, 2012
Publication date:
December 19, 2013
Inventors:
Hans NAUWYNCK, Gerald MISINZO, Sven ARNOUTS
Abstract: The present disclosure provides methods for preparing vesicles. In one aspect, the methods involve providing a molten mixture of vesicle-forming lipids and adding the molten mixture of vesicle-forming lipids to an aqueous solution comprising an antigen such that antigen-containing vesicles are formed, wherein in the step of adding the molten mixture of vesicle forming lipids is at a temperature of less than 120° C. In another aspect, the methods involve providing a molten mixture of vesicle-forming lipids and adding an aqueous solution comprising an antigen to the molten mixture of vesicle-forming lipids such that antigen-containing vesicles are formed, wherein the resulting mixture is placed under temperature-controlled conditions of less than 60° C. In yet another aspect, the methods involve providing a solution of vesicle forming lipids and adding the solution of vesicle-forming lipids to an aqueous solution comprising an antigen by injection such that antigen-containing vesicles are formed.
Type:
Application
Filed:
January 13, 2012
Publication date:
December 5, 2013
Applicant:
VARIATION BIOTECHNOLOGIES, INC.
Inventors:
David E. Anderson, Yvonne Perrie, Marc Kirchmeier, Jitinder Singh Wilkhu
Abstract: The present invention relates to the field of vaccines and medicaments for the prophylaxis and treatment of infectious diseases in ruminants. In particular, it relates to inactivated Schmallenberg virus (SBV) useful as vaccine or medicament for preventing or treating viremia, the transmission and clinical symptoms, in particular malformations in newborn ruminants such as cattle, sheep and goats, induced by SBV.
Type:
Application
Filed:
May 29, 2013
Publication date:
December 5, 2013
Applicant:
BOEHRINGER INGELHEIM VETMEDICA GMBH
Inventors:
Veljko NIKOLIN, Konrad STADLER, Axel LISCHEWSKI, Alexander BRIX, Jeffrey P. KNITTEL, Katharina Hedwig TOEPFER
Abstract: Methods of modulating the immune response using pharmaceutical compositions containing crystalline adjuvants are described. In various embodiments the crystalline adjuvants are selected from the group consisting of monosodium urate (MSU), xanthine, basic calcium phosphate (BCP), calcium pyrophosphate dihydrate (CPPD), hydroxyapatite, calcium oxalate, cholesterol, lipid liquid, other crystalline lipids, lithium heparin, talc, and starch.
Abstract: The invention provides compositions and methods for the prophylaxis or treatment of diseases or disorders in a subject (e.g., a mammal, such as a human) including, e.g., diseases or disorders caused by biological agents, autoimmune diseases, and cancer. The compositions include a delivery vector (e.g., a viral vector, such as an Ad5 vector) encoding an interferon (e.g., IFN-?), and are provided to the subject by, e.g., intranasal or pulmonary administration.
Abstract: Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations.
Abstract: The present invention relates to recombinant cells as well as to methods for the generation of non-segmented negative-sense single-stranded RNA viruses (NNV or mononegavirales) from cloned deoxyribonucleic acid (cDNA), especially from measles virus and in particular from attenuated strains such as those approved for vaccination, in particular from the attenuated Schwarz measles virus and various recombinant Schwarz measles-based viruses expressing heterologous sequences. Such rescued viruses can be used, after amplification, as vaccines for immunization against measles and/or against the heterologous peptides or proteins expressed.
Type:
Grant
Filed:
December 21, 2007
Date of Patent:
November 19, 2013
Assignee:
Institut Pasteur
Inventors:
Frédéric Tangy, Pierre Charneau, Yves Jacob
Abstract: The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell.
Abstract: This invention relates to vaccines and in particular to the combination of non-integrating, replication-incompetent retroviral vectors (NIV) with virus-like particle (VLP) vaccines to induce an immune response in an animal host following administration to the host. This combination results in a novel vaccine strategy for delivering priming and boost doses, wherein an effective amount of an NIV is administered to the host, followed by an effective amount of a VLP. The concept can be broadly applied to infectious disease vaccines and also to cancer vaccines.